Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 6/2023

Open Access 05-10-2023 | Myocardial Infarction

The role and medical prospects of long non-coding RNAs in cardiovascular disease

Authors: Najung Kim, Woo-Young Chung, Je-Yoel Cho

Published in: Heart Failure Reviews | Issue 6/2023

Login to get access

Abstract

Cardiovascular disease (CVD) has reached epidemic proportions and is a leading cause of death worldwide. One of the long-standing goals of scientists is to repair heart tissue damaged by various forms of CVD such as cardiac hypertrophy, dilated cardiomyopathy, myocardial infarction, heart fibrosis, and genetic and developmental heart defects such as heart valve deformities. Damaged or defective heart tissue has limited regenerative capacity and results in a loss of functioning myocardium. Advances in transcriptomic profiling technology have revealed that long noncoding RNA (lncRNA) is transcribed from what was once considered “junk DNA.” It has since been discovered that lncRNAs play a critical role in the pathogenesis of various CVDs and in myocardial regeneration. This review will explore how lncRNAs impact various forms of CVD as well as those involved in cardiomyocyte regeneration. Further, we discuss the potential of lncRNAs as a therapeutic modality for treating CVD.
Literature
1.
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al (2001) The sequence of the human genome. Science 291:1304–1351PubMedCrossRef
2.
Sequencing HG (2004) Finishing the euchromatic sequence of the human genome. Nature 431:931–945CrossRef
3.
4.
Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ et al (2015) Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene 34:5003–5011PubMedPubMedCentralCrossRef
5.
Lee H, Zhang Z, Krause HM (2019) Long noncoding RNAs and repetitive elements: junk or intimate evolutionary partners? Trends Genet 35:892–902PubMedCrossRef
6.
Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R (2018) Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet 19:535–548PubMedPubMedCentralCrossRef
7.
Statello L, Guo C-J, Chen L-L, Huarte M (2021) Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol 22:96–118PubMedCrossRef
8.
Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y et al (2020) Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers. Front Oncol 10:598817PubMedPubMedCentralCrossRef
9.
Gao L, Zhao Y, Ma X, Zhang L (2021) Integrated analysis of lncRNA–miRNA–mRNA ceRNA network and the potential prognosis indicators in sarcomas. BMC Med Genomics 14:1–11CrossRef
10.
de Goede OM, Nachun DC, Ferraro NM, Gloudemans MJ, Rao AS, Smail C et al (2021) Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell 184:2633–2648. e19
11.
Organization WH (2019) Global action plan for the prevention and control of NCDs 2013–2020. 2013. Geneva: WHO
12.
Cheng Y, Mou L, Li Z (2022) Trends in adherence to recommended physical activity and its association with cardiovascular risk factors in US adults with cardiovascular disease: a cross-sectional study. BMC Cardiovasc Disord 22:1–7CrossRef
13.
14.
Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS et al (2022) Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 145:e153–e639PubMedCrossRef
15.
Lu L, Liu M, Sun R, Zheng Y, Zhang P (2015) Myocardial infarction: symptoms and treatments. Cell Biochem Biophys 72:865–867PubMedCrossRef
16.
Ojha N, Dhamoon AS (2021) Myocardial infarction. StatPearls [Internet]: StatPearls Publishing
17.
18.
Millett ER, Peters SA, Woodward M (2018) Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ 363:3–6
19.
Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I et al (2016) Lifelong gender gap in risk of incident myocardial infarction: the Tromsø study. JAMA Intern Med 176:1673–1679PubMedCrossRef
20.
Li M, Han Y, Chen Y, Li B, Chen G, Chen X et al (2021) LncRNA Snhg1-driven self-reinforcing regulatory network promoted cardiac regeneration and repair after myocardial infarction. Theranostics 11:9397PubMedPubMedCentralCrossRef
21.
Li L, Wang J, Zhang H (2018) LncRNA-CARl in a rat model of myocardial infarction. Eur Rev Med Pharmacol Sci 22:4332–4340PubMed
22.
Wang K, Long B, Zhou L-Y, Liu F, Zhou Q-Y, Liu C-Y et al (2014) CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun 5:1–13
23.
Mo Y, Wu H, Zheng X, Xu L, Liu L, Liu Z (2021) LncRNA CHRF aggravates myocardial ischemia/reperfusion injury by enhancing autophagy via modulation of the miR-182-5p/ATG7 pathway. J Biochem Mol Toxicol 35:e22709PubMedCrossRef
24.
Niu X, Pu S, Ling C, Xu J, Wang J, Sun S et al (2020) lncRNA Oip5-as1 attenuates myocardial ischaemia/reperfusion injury by sponging miR-29a to activate the SIRT1/AMPK/PGC1α pathway. Cell Prolif 53:e12818PubMedPubMedCentralCrossRef
25.
Gao L, Liu Y, Guo S, Yao R, Wu L, Xiao L et al (2017) Circulating long noncoding RNA HOTAIR is an essential mediator of acute myocardial infarction. Cell Physiol Biochem 44:1497–1508PubMedCrossRef
26.
Yao J, Ma R, Wang C, Zhao G (2022) LncRNA-HOTAIR inhibits H9c2 apoptosis after acute myocardial infarction via miR-206/FN1 axis. Biochem Genet 1–12
27.
Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis–a short review of causes and therapeutic strategies. Adv Drug Deliv Rev 146:77–82PubMedCrossRef
28.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal) 74:1037–1147PubMedCrossRef
29.
Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K et al (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47:711–717PubMedCrossRef
30.
Piccoli M-T, Gupta SK, Viereck J, Foinquinos A, Samolovac S, Kramer FL et al (2017) Inhibition of the cardiac fibroblast–enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction. Circ Res 121:575–583PubMedCrossRef
31.
Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting C-C, Alexanian M et al (2017) The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9:eaai9118
32.
Huang S, Zhang L, Song J, Wang Z, Huang X, Guo Z et al (2019) Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. J Cell Physiol 234:2997–3006PubMedCrossRef
33.
Qu X, Du Y, Shu Y, Gao M, Sun F, Luo S et al (2017) MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep 7:1–11
34.
Brieler J, Breeden MA, Tucker J (2017) Cardiomyopathy: an overview. Am Fam Physician 96:640–646PubMed
35.
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA et al (2022) Management of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 79:390–414PubMedCrossRef
36.
Han P, Li W, Lin C-H, Yang J, Shang C, Nurnberg ST et al (2014) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514:102–106PubMedPubMedCentralCrossRef
37.
Zhang J, Gao C, Meng M, Tang H (2016) Long noncoding RNA MHRT protects cardiomyocytes against H2O2-induced apoptosis. Biomol Ther 24:19CrossRef
38.
Forini F, Nicolini G, Kusmic C, D’Aurizio R, Mercatanti A, Iervasi G et al (2020) T3 critically affects the Mhrt/Brg1 axis to regulate the cardiac MHC switch: role of an epigenetic cross-talk. Cells 9:2155PubMedPubMedCentralCrossRef
39.
Zhang L-E, Wu Y-J, Zhang S-L (2019) Circulating lncRNA MHRT predicts survival of patients with chronic heart failure. J Geriatr Cardiol JGC 16:818PubMed
40.
Wang Z, Zhang X-J, Ji Y-X, Zhang P, Deng K-Q, Gong J et al (2016) The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med 22:1131–1139PubMedPubMedCentralCrossRef
41.
Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M et al (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8:326ra22-ra22
42.
Sun X, Lv J, Dou L, Chen D, Zhu Y, Hu X (2020) LncRNA NEAT1 promotes cardiac hypertrophy through microRNA-19a-3p/SMYD2 axis. Eur Rev Med Pharmacol Sci 24:1367–1377PubMed
43.
Andersson C, Schou M, Schwartz B, Vasan RS, Christiansen MN, D’Souza M et al (2022) Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. IJC Heart Vasc 41:101065CrossRef
44.
Hagar A, Pu X-B, Chen S-J, Shah J-P, Chen M (2019) Clinical characteristics, treatment and prognosis of patients with idiopathic dilated cardiomyopathy: a tertiary center experience. J Geriatr Cardiol JGC 16:320PubMed
45.
Fan J, Li H, Xie R, Zhang X, Nie X, Shi X et al (2021) LncRNA ZNF593-AS alleviates contractile dysfunction in dilated cardiomyopathy. Circ Res 128:1708–1723PubMedCrossRef
46.
Zhang Y, Zhang M, Xu W, Chen J, Zhou X (2017) The long non-coding RNA H19 promotes cardiomyocyte apoptosis in dilated cardiomyopathy. Oncotarget 8:28588PubMedPubMedCentralCrossRef
47.
Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S et al (2009) Evidence for cardiomyocyte renewal in humans. Science 324:98–102PubMedPubMedCentralCrossRef
48.
Giacca M (2020) Cardiac regeneration after myocardial infarction: an approachable goal. Curr Cardiol Rep 22:1–8CrossRef
49.
Doppler SA, Deutsch M-A, Serpooshan V, Li G, Dzilic E, Lange R et al (2017) Mammalian heart regeneration: the race to the finish line. Circ Res 120:630–632PubMedPubMedCentralCrossRef
50.
Chen Y, Li X, Li B, Wang H, Li M, Huang S et al (2019) Long non-coding RNA ECRAR triggers post-natal myocardial regeneration by activating ERK1/2 signaling. Mol Ther 27:29–45PubMedCrossRef
51.
Li B, Hu Y, Li X, Jin G, Chen X, Chen G et al (2018) Sirt1 antisense long noncoding RNA promotes cardiomyocyte proliferation by enhancing the stability of Sirt1. J Am Heart Assoc 7:e009700PubMedPubMedCentralCrossRef
52.
Wang J, Chen X, Shen D, Ge D, Chen J, Pei J et al (2019) A long noncoding RNA NR_045363 controls cardiomyocyte proliferation and cardiac repair. J Mol Cell Cardiol 127:105–114PubMedCrossRef
53.
Cai B, Ma W, Wang X, Sukhareva N, Hua B, Zhang L et al (2020) Targeting LncDACH1 promotes cardiac repair and regeneration after myocardium infarction. Cell Death Differ 27:2158–2175PubMedPubMedCentralCrossRef
54.
Chen G, Li H, Li X, Li B, Zhong L, Huang S et al (2018) Loss of long non-coding RNA CRRL promotes cardiomyocyte regeneration and improves cardiac repair by functioning as a competing endogenous RNA. J Mol Cell Cardiol 122:152–164PubMedCrossRef
55.
Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML et al (2013) Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152:570–583PubMedPubMedCentralCrossRef
56.
Guo X, Xu Y, Wang Z, Wu Y, Chen J, Wang G et al (2018) A Linc1405/Eomes complex promotes cardiac mesoderm specification and cardiogenesis. Cell Stem Cell 22:893–908. e6
57.
Kim N-J, Lee K-H, Son Y, Nam A-R, Moon E-H, Pyun J-H et al (2021) Spatiotemporal expression of long noncoding RNA Moshe modulates heart cell lineage commitment. RNA Biol 18:640–654PubMedPubMedCentralCrossRef
58.
Fathi DB (2020) Strategies to target long non-coding RNAs in cancer treatment: progress and challenges. Egyp J Med Human Genet 21:1–15
59.
60.
Rao DD, Vorhies JS, Senzer N, Nemunaitis J (2009) siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61:746–759PubMedCrossRef
61.
Ling H (2016) Non-coding RNAs: therapeutic strategies and delivery systems. Non-coding RNAs in Colorectal Cancer. Adv Exp Med Biol 937(229–237):231–233. Springer
62.
63.
Montes M, Arnes L (2021) lncRNAs: potential therapeutic targets and biomarkers for pancreatic cancer? Expert Opin Ther Targets 25:521–528PubMedCrossRef
64.
Li X, Qi H, Cui W, Wang Z, Fu X, Li T et al (2022) Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis. Mol Ther 3121
65.
Park JY, Lee JE, Park JB, Yoo H, Lee S-H, Kim JH (2014) Roles of long non-coding RNAs on tumorigenesis and glioma development. Brain Tumor Res Treat 2:1PubMedPubMedCentralCrossRef
66.
Parasramka MA, Maji S, Matsuda A, Yan IK, Patel T (2016) Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther 161:67–78PubMedPubMedCentralCrossRef
67.
68.
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267PubMedCrossRef
69.
Chen Y, Li Z, Chen X, Zhang S (2021) Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B 11:340–354PubMedCrossRef
70.
Bisserier M, Sun XQ, Fazal S, Turnbull IC, Bonnet S, Hadri L (2022) Novel insights into the therapeutic potential of lung-targeted gene transfer in the most common respiratory diseases. Cells 11:3–12CrossRef
71.
Tenchov R, Bird R, Curtze AE, Zhou QQ (2021) Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15:16982–17015PubMedCrossRef
72.
Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (1987) Vesicle Formation during reticulocyte maturation - association of plasma-membrane activities with released vesicles (exosomes). J Biol Chem 262:9412–9420PubMedCrossRef
73.
Han SQ, Qi YQ, Luo YM, Chen XP, Liang HF (2021) Exosomal long non-coding RNA: interaction between cancer cells and non-cancer cells. Front Oncol 10:1–7CrossRef
74.
Andaloussi EL, S, Lakhal S, Mager I, Wood MJA. (2013) Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 65:391–397PubMedCrossRef
75.
Tao SC, Guo SC, Zhang CQ (2018) Modularized extracellular vesicles: the dawn of prospective personalized and precision medicine. Adv Sci 5:2–9
76.
Lin Y, Wu JH, Gu WH, Huang YL, Tong ZC, Huang LJ et al (2018) Exosome-liposome hybrid nanoparticles deliver CRISPR/Cas9 system in MSCs. Adv Sci 5
77.
78.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:e29–e322
79.
Reimer KA, Tanaka M, Murry CE, Richard VJ, Jennings RB (1990) Evaluation of free radical injury in myocardium. Toxicol Pathol 18:470–480PubMedCrossRef
80.
Richard V, Murry C, Jennings R, Reimer K (1990) Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications. Fundam Clin Pharmacol 4:85–103PubMedCrossRef
81.
Kloner RA (1988) Introduction to the role of oxygen radicals in myocardial ischemia and infarction. Free Radical Biol Med 4:5–7CrossRef
82.
Jain A, Mohan A, Gupta O, Jajoo U, Kalantri S, Srivastava L (2000) Role of oxygen free radicals in causing endothelial damage in acute myocardial infarction. J Assoc Physicians India 48:478–480PubMed
83.
Sharma V, Bell RM, Yellon DM (2012) Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother 13:1153–1175PubMedCrossRef
84.
Batchelor R, Liu DH, Bloom J, Noaman S, Chan W (2020) Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta-analysis. Catheter Cardiovasc Interv 96:76–88PubMedCrossRef
85.
Hoedemaker NP, Roolvink V, de Winter RJ, van Royen N, Fuster V, García-Ruiz JM et al (2020) Early intravenous beta-blockers in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a patient-pooled meta-analysis of randomized clinical trials. Eur Heart J Acute Cardiovasc Care 9:469–477PubMedCrossRef
86.
87.
Mathur A, Fernández-Avilés F, Bartunek J, Belmans A, Crea F, Dowlut S et al (2020) The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial. Eur Heart J 41:3702–3710PubMedPubMedCentralCrossRef
88.
Nicolau JC, Furtado RH, Silva SA, Rochitte CE, Rassi A Jr, Moraes JB Jr et al (2018) Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: a multicenter, double-blind randomized trial. Clin Cardiol 41:392–399PubMedPubMedCentralCrossRef
89.
Quyyumi AA, Vasquez A, Kereiakes DJ, Klapholz M, Schaer GL, Abdel-Latif A et al (2017) PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res 120:324–331PubMedCrossRef
90.
Lindeman A, Pepine CJ, March KL (2020) Cardiac stem cell therapy among Clinics of Uncertain Regulatory Status (COURS): under-regulated, under-observed, incompletely understood. J Transl Med 18:1–7CrossRef
91.
Xia D, Sui R, Zhang Z (2019) Administration of resveratrol improved Parkinson’s disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR-129/SNCA signaling pathway. J Cell Biochem 120:4942–4951PubMedCrossRef
92.
Geng W, Guo X, Zhang L, Ma Y, Wang L, Liu Z et al (2018) Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway. Biomed Pharmacother 107:484–494PubMedCrossRef
93.
94.
Wei D, Yun L, Dejun X, Cong L, He J-H, Yan L (2019) Curcumin combining with si-MALAT1 inhibits the invasion and migration of colon cancer SW480 cells. Braz J Pharm Sci 55
95.
Yuan X, Wang J, Tang X, Li Y, Xia P, Gao X (2015) Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med 13:1–11CrossRef
96.
97.
Rüger J, Ioannou S, Castanotto D, Stein CA (2020) Oligonucleotides to the (gene) rescue: FDA approvals 2017–2019. Trends Pharmacol Sci 41:27–41PubMedCrossRef
98.
Crooke ST (2007) Antisense drug technology: principles, strategies, and applications. CRC press
99.
100.
Hueso M, Mallén A, Suñé-Pou M, Aran JM, Suñé-Negre JM, Navarro E (2021) ncRNAs in therapeutics: challenges and limitations in nucleic acid-based drug delivery. Int J Mol Sci 22:11596PubMedPubMedCentralCrossRef
101.
Liu C-Y, Zhang Y-H, Li R-B, Zhou L-Y, An T, Zhang R-C et al (2018) LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription. Nat Commun 9:1–12
102.
Ponnusamy M, Liu F, Zhang Y-H, Li R-B, Zhai M, Liu F et al (2019) Long noncoding RNA CPR (cardiomyocyte proliferation regulator) regulates cardiomyocyte proliferation and cardiac repair. Circulation 139:2668–2684PubMedCrossRef
103.
Li X, Zhou J, Huang K (2017) Inhibition of the lncRNA Mirt1 attenuates acute myocardial infarction by suppressing NF-κB activation. Cell Physiol Biochem 42:1153–1164PubMedCrossRef
104.
Zhuang A, Calkin AC, Lau S, Kiriazis H, Donner DG, Liu Y et al (2021) Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner. iScience 24:102537
105.
Wang K, Liu C-Y, Zhou L-Y, Wang J-X, Wang M, Zhao B et al (2015) APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun 6:1–11
106.
Zeng H, Hu F, Duan Y, Li H, Wang Y (2022) Expression of lncRNA APF in peripheral blood of patients with acute myocardial infarction caused by coronary heart disease and its clinical significance. Int Heart J 63:742–748PubMedCrossRef
107.
Cai B, Ma W, Ding F, Zhang L, Huang Q, Wang X et al (2018) The long noncoding RNA CAREL controls cardiac regeneration. J Am Coll Cardiol 72:534–550PubMedCrossRef
108.
Liang H, Su X, Wu Q, Shan H, Lv L, Yu T et al (2020) LncRNA 2810403D21Rik/Mirf promotes ischemic myocardial injury by regulating autophagy through targeting Mir26a. Autophagy 16:1077–1091PubMedCrossRef
109.
Long B, Li N, Xu X-X, Li X-X, Xu X-J, Guo D et al (2018) Long noncoding RNA FTX regulates cardiomyocyte apoptosis by targeting miR-29b-1-5p and Bcl2l2. Biochem Biophys Res Commun 495:312–318PubMedCrossRef
110.
Li X, He X, Wang H, Li M, Huang S, Chen G et al (2018) Loss of AZIN2 splice variant facilitates endogenous cardiac regeneration. Cardiovasc Res 114:1642–1655PubMedPubMedCentralCrossRef
111.
Huang L, Guo B, Liu S, Miao C, Li Y (2020) Inhibition of the LncRNA Gpr19 attenuates ischemia-reperfusion injury after acute myocardial infarction by inhibiting apoptosis and oxidative stress via the miR-324-5p/Mtfr1 axis. IUBMB life 72:373–383PubMedCrossRef
112.
Wang Q-S, Zhou J, Li X (2020) LncRNA UCA1 protects cardiomyocytes against hypoxia/reoxygenation induced apoptosis through inhibiting miR-143/MDM2/p53 axis. Genomics 112:574–580PubMedCrossRef
113.
Yu J, Yang Y, Xu Z, Lan C, Chen C, Li C et al (2020) Long noncoding RNA Ahit protects against cardiac hypertrophy through SUZ12 (suppressor of Zeste 12 protein homolog)-mediated downregulation of MEF2A (myocyte enhancer factor 2A). Circ Heart Fail 13:e006525
114.
Viereck J, Bührke A, Foinquinos A, Chatterjee S, Kleeberger JA, Xiao K et al (2020) Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy. Eur Heart J 41:3462–3474PubMedPubMedCentralCrossRef
115.
Wang K, Liu F, Zhou L-Y, Long B, Yuan S-M, Wang Y et al (2014) The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114:1377–1388PubMedCrossRef
116.
Lv L, Li T, Li X, Xu C, Liu Q, Jiang H et al (2018) The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. Mol Ther Nucleic Acids 10:387–397PubMedCrossRef
117.
Lai Y, He S, Ma L, Lin H, Ren B, Ma J et al (2017) HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Mol Cell Biochem 432:179–187PubMedCrossRef
118.
Li Y, Wang J, Sun L, Zhu S (2018) LncRNA myocardial infarction-associated transcript (MIAT) contributed to cardiac hypertrophy by regulating TLR4 via miR-93. Eur J Pharmacol 818:508–517PubMedCrossRef
119.
Zhu X, Yuan Y, Rao S, Wang P (2016) LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci 20:3653–3660PubMed
120.
Zhang Q, Wang F, Wang F, Wu N (2020) Long noncoding RNA MAGI1-IT1 regulates cardiac hypertrophy by modulating miR-302e/DKK1/Wnt/beta-catenin signaling pathway. J Cell Physiol 235:245–253PubMedCrossRef
121.
Wang Y, Cao R, Yang W, Qi B (2019) SP1-SYNE1-AS1-miR-525-5p feedback loop regulates Ang-II-induced cardiac hypertrophy. J Cell Physiol 234:14319–14329PubMedCrossRef
122.
Xiao L, Gu Y, Sun Y, Chen J, Wang X, Zhang Y et al (2019) The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR-101. J Cell Physiol 234:13680–13692PubMedCrossRef
123.
Trembinski DJ, Bink DI, Theodorou K, Sommer J, Fischer A, van Bergen A et al (2020) Aging-regulated anti-apoptotic long non-coding RNA Sarrah augments recovery from acute myocardial infarction. Nat Commun 11:1–14CrossRef
124.
Anderson KM, Anderson DM, McAnally JR, Shelton JM, Bassel-Duby R, Olson EN (2016) Transcription of the non-coding RNA upperhand controls Hand2 expression and heart development. Nature 539:433–436PubMedPubMedCentralCrossRef
Metadata
Title
The role and medical prospects of long non-coding RNAs in cardiovascular disease
Authors
Najung Kim
Woo-Young Chung
Je-Yoel Cho
Publication date
05-10-2023
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 6/2023
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-023-10342-1

Other articles of this Issue 6/2023

Heart Failure Reviews 6/2023 Go to the issue

ReviewPaper

Cardiopulmonary exercise testing criteria for advanced therapies in patients with heart failure

EditorialNotes

Heart failure and exercise cardiac rehabilitation in the 21st Century

ReviewPaper

Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease

ReviewPaper

Cardiac transplant and exercise cardiac rehabilitation

ReviewPaper

Cost-effectiveness of cardiovascular magnetic resonance imaging compared to common strategies in the diagnosis of coronary artery disease: a systematic review

ReviewPaper

Lipoprotein(a) and heart failure: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits